Strategies for long-acting drug design.
10.12122/j.issn.1673-4254.2025.01.24
- Author:
Muqi HUANG
1
;
Zheng CAI
1
;
Shuwen LIU
1
Author Information
1. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Review
- Keywords:
drug design;
long-acting drugs;
monoclonal antibodies;
nucleic acid drugs;
small molecule drugs
- MeSH:
Humans;
Drug Design;
Antibodies, Monoclonal/chemistry*;
Nucleic Acids;
Precision Medicine;
Delayed-Action Preparations
- From:
Journal of Southern Medical University
2025;45(1):206-212
- CountryChina
- Language:English
-
Abstract:
With advances of drug design and preparation technology, the development of long-acting drugs has become an important research focus in precision medicine and chronic disease management. These drugs are designed to improve the patients' compliance and quality of life by achieving prolonged maintenance of an effective drug concentration in the body with a reduced dosing frequency. Small molecule drugs, monoclonal antibodies and nucleic acid drugs all have their own difficulties in achieving long actions, which can be especially challenging for the latter two because of their structural complexity. This review provides an overview of the strategies for designing long-acting small molecule drugs, monoclonal antibodies, and nucleic acid drugs.
